{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:03:00Z","timestamp":1780531380101,"version":"3.54.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clinre.2026.102831","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T14:56:49Z","timestamp":1776524209000},"page":"102831","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chemotherapy as a salvage strategy after immunotherapy failure in advanced hepatocellular carcinoma: A case series"],"prefix":"10.1016","volume":"50","author":[{"given":"Yasemin","family":"Evlendi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonca","family":"Eldem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevtap Arslan","family":"Sarikaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suayib","family":"Yalc\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Dizdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.clinre.2026.102831_bib0001","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clinre.2026.102831_bib0002","doi-asserted-by":"crossref","first-page":"592","DOI":"10.21037\/hbsn-22-143","article-title":"Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma","volume":"11","author":"Kudo","year":"2022","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"8","key":"10.1016\/j.clinre.2026.102831_bib0003","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/cts.13544","article-title":"Exposure-response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)","volume":"16","author":"Sangro","year":"2023","journal-title":"Clin Transl Sci"},{"issue":"6","key":"10.1016\/j.clinre.2026.102831_bib0004","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.7314\/APJCP.2012.13.6.2985","article-title":"Clinicopathological characteristics of hepatocellular carcinoma in Turkey","volume":"13","author":"Dogan","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"issue":"45","key":"10.1016\/j.clinre.2026.102831_bib0005","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000035950","article-title":"The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter real-world study from Turkey","volume":"102","author":"Akyildiz","year":"2023","journal-title":"Medicine"},{"issue":"7","key":"10.1016\/j.clinre.2026.102831_bib0006","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.21037\/jtd-23-858","article-title":"Efficacy of second-line chemotherapy after immunotherapy in advanced non-small cell lung cancer","volume":"15","author":"Hirata","year":"2023","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.clinre.2026.102831_bib0007","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fonc.2020.00070","article-title":"Immunotherapy potentiates the effect of chemotherapy in metastatic melanoma-A retrospective study","volume":"10","author":"Hadash-Bengad","year":"2020","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.clinre.2026.102831_bib0008","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L","article-title":"Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial","volume":"62","author":"Lai","year":"1988","journal-title":"Cancer"},{"issue":"28","key":"10.1016\/j.clinre.2026.102831_bib0009","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1200\/JCO.2012.44.5643","article-title":"Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil\/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia","volume":"31","author":"Qin","year":"2013","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clinre.2026.102831_bib0010","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1093\/annonc\/mdw323","article-title":"Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial","volume":"27","author":"Ikeda","year":"2016","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.clinre.2026.102831_bib0011","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/ajco.12081","article-title":"Transarterial chemoembolization in hepatocellular carcinoma with vascular invasion or extrahepatic metastasis: a systematic review","volume":"9","author":"Zhao","year":"2013","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.clinre.2026.102831_bib0012","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2021.11.022","article-title":"Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis","volume":"162","author":"Goldinger","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clinre.2026.102831_bib0013","volume":"4","author":"Sasaki","year":"2020"},{"issue":"1","key":"10.1016\/j.clinre.2026.102831_bib0014","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jtho.2017.10.011","article-title":"Increased response rates to salvage chemotherapy administered after PD-1\/PD-L1 inhibitors in patients with non-small cell lung cancer","volume":"13","author":"Park","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"7","key":"10.1016\/j.clinre.2026.102831_bib0015","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/s41416-021-01486-8","article-title":"Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma","volume":"125","author":"Bouchereau","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinre.2026.102831_bib0016","doi-asserted-by":"crossref","DOI":"10.2217\/fon-2022-0642","article-title":"The benefit of immunotherapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis","author":"Guven","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.clinre.2026.102831_bib0017","article-title":"Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.clinre.2026.102831_bib0018","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.3389\/fimmu.2018.01310","article-title":"Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors","volume":"9","author":"Weber","year":"2018","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.clinre.2026.102831_bib0019","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.97828","article-title":"CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy","volume":"3","author":"Yan","year":"2018","journal-title":"JCI Insight"},{"issue":"14","key":"10.1016\/j.clinre.2026.102831_bib0020","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clinre.2026.102831_bib0021","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4103\/0971-5851.96968","article-title":"Gemcitabine and cisplatin-based combination chemotherapy in advanced hepatocellular carcinoma: an Indian experience","volume":"33","author":"Pande","year":"2012","journal-title":"Indian J Med Paediatr Oncol"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740126000781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740126000781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T23:26:21Z","timestamp":1780529181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740126000781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2210740126000781"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2026.102831","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapy as a salvage strategy after immunotherapy failure in advanced hepatocellular carcinoma: A case series","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2026.102831","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102831"}}